Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the ...

Analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for Arvinas in a report issued on Wednesday, ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Arvinas Inc (NASDAQ:ARVN), a biotechnology company focused on developing therapies for cancer and other difficult-to-treat diseases, has been making waves in the pharmaceutical industry with its ...

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The ...

Citi analyst Yigal Nochomovitz maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of $97.00. The ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Citi analyst Yigal Nochomovitz reiterated a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report) yesterday and set a price target of ...

Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment strategy that prominently featured an accelerated book building process aimed ...